cbdMD’s Post

Breaking Barriers: cbdMD's Research Validates Safe CBD Upper Dose The publication includes three separate OECD experiments on rodents performed by a Eurofins lab on the Company's proprietary broad spectrum blend to investigate 1) prenatal development, 2) a 14-day dose-range finding study, and 3) a 90-day subchronic safety study with a recovery period. The prenatal screening study did not identify any substance-related changes in key areas related to maternal health. The 14-day study demonstrated that animals were safely able to consume up to 460 mg/kg daily of the blend of cannabinoids. The 90-day repeated dose safety study was designed following the 14-day study data on the cannabinoid blend with a recovery period at the end. In the 90-day study, the animals did not exhibit any significant adverse effects. Based on these findings, the study determined that cbdMD's proprietary broad spectrum blend is safe when consumed in an average person at 2.29 mg/kg of body weight daily (i.e., 160 mg per day in a 70 kg or 154lb human), as used in dietary supplement products. EurofinscbdMDFundación CANNAMediSmart CR https://lnkd.in/g3NKuPdn

Novo Nordisk recently published preliminary results from a study of one of their products aimed at treating obesity, semaglutide or Wegowy. According to the results of the study, which included 17,604 overweight or obese adults, after five years, patients who took 2.4 mg of semaglutide had a 20% lower chance of developing heart attack and stroke. The results have not yet been published in medical journals as they are undergoing peer review, however, Novo Nordisk has already made a preliminary announcement and will reveal details at medical conferences this year. Wegowy has been shown to be not only effective in weight loss (according to the results, about 86.5% of patients taking this drug achieved a reduction of at least 5% of their body weight), but also cardioprotective. Its significant disadvantage is its price, but now a number of countries are already considering ways to cover all or part of the cost of this drug with insurance for patients who have indications for taking this drug. In fact, this study is not only another confirmation, but also a great demonstration that, like many other diseases, obesity can be managed and the risks it poses to the body can be reduced. Due to the stigmatisation of overweight and fatphobia in society, people often forget that there are conditions such as preobesity and obesity itself, which are a premorbid condition and a disease respectively. Obesity is often perceived in society as a result of a promiscuous lifestyle, and as a consequence, patients with pre-obesity and obesity are often advised only to "pull themselves together", "exercise", "stop eating so much" and similar. In reality, for many people, lifestyle modification is a difficult task, accompanied by breakdowns and serious psychological discomfort. The lack of visible results in such cases demotivates people and plunges them deeper into depression and despair. Approaching obesity and preobesity as a disease and pre-morbid condition will help patients and their physicians realise that there may be a medical treatment added to lifestyle modification. Destigmatising obesity and seeing it strictly as a disease that may require treatment, as I see it, may increase the effectiveness of weight management in obese patients.

Interesting read

Simultaneously unsurprising but also big deal: Novo Nordisk trial semaglutide (Wegovy/Ozempic) can reduce risk of major adverse cardiovascular event (heart attack, stroke, etc) by 20% vs placebo over 5 yrs Will be interesting to see (a) if this effect is shared by other GLP-1 analogs and (b) how insurance companies will respond in coverage given that Novo Nordisk (and Lilly and everyone else with a GLP-1 analog) will likely be reaching for broader indications than weight loss / diabetes now

Interesting read

🌟 A Milestone in My Clinical Research Coordinator's Journey: Thrilled to Share News of the FLOW Trial Success! 🌟 Excited to share the success of the FLOW trial, marking a significant chapter in my journey as one of the lead clinical research coordinators at the Toronto General Hospital site for this groundbreaking study. This week, Novo Nordisk revealed a groundbreaking achievement - a remarkable 24% reduction in kidney disease progression and related deaths with semaglutide (Ozempic). The trial not only confirmed its potential but also surpassed secondary endpoints, marking a substantial breakthrough. Witnessing the publication of these trial results, it prompted a deeper reflection on my professional journey. My initial passion as a registered nurse to help people has evolved into a profound eagerness to contribute more through the transformative power of research. This value has guided me as a clinical research coordinator and will persist as I approach the completion of my Master of Science in Regulatory Affairs program. It has been an incredible journey working on clinical trials that has led to the approval of drugs such as Jardiance, Forxiga, and Invokana for diabetes and chronic kidney disease - a humbling experience beyond words. Now, adding the Flow Trial for Ozempic is another remarkable chapter. I appreciate the significance of this moment and look forward to the positive impact our shared efforts may have on the future of medical research. #ClinicalResearch #ClinicalTrials #ClinicalDataManagement #Ozempic #FLOWtrial #NovoNordisk #chronickidneydisease #CKD #Diabetes

Novo Nordisk reported topline results of the SELECT trial today showing treatment with semaglutide decreased the risk of cardiovascular death, heart attack, and stroke in people with obesity and cardiovascular disease by 20%. The results were expected since we already have decades of data with bariatric surgery showing lower rates of cardiovascular events, cancer, and all-cause mortality. This should prompt us to have more nuanced, serious conversations. Obesity is a disease and treating it lowers the risk of hard endpoints. Those who believe in the Healthy at Every Size concept should #followthescience. We must get serious about combatting #weightbias at every turn, which is what I believe prompted the HAES movement to begin with. We must admit that treating obesity at this time is very costly. Surgery is a cost effective option for many, but is not right for everyone. At the same time, not treating obesity is costly too, not only in terms of the human cost—which should not be ignored—but also in terms of economic costs. If we don't want to bequeath our current predicament to generation after generation in the future, we need to start talking about obesity prevention. Obesity prevention and treatment are different. There is some overlap, but not as much as most people think. Obesity needs to be thought of as much more than a health problem. It is a societal problem affecting every facet of society and industry. Continuing to discuss it as only a healthcare problem is limiting the scope of the problem and its potential remedies. #obesitytreatment #obesitymedicine

We just announced findings from blinded data presented at #CTAD23, with highlights from our press release below. The data suggest that NE3107 is biologically active and may have an impact across endpoints among mild to moderate #AlzheimersDisease patients. *** KEY INFORMATION ***   - Statistically significant population changes from baseline were observed for all primary and secondary cognitive and functional assessments measured   - An apparent significant reduction in amyloid burden from baseline was observed in the population   - Statistically significant increases in insulin and beta cell function were observed without any hypoglycemia, which suggests target engagement and lends support for a previously identified potential mechanism of action for NE3107   - Rate and nature of adverse events consistent with prior clinical studies of NE3107   - Unblinded, topline data expected to be announced in late November/early December

Interesting Article

Research on dietary alpha-ketoglutarate as a supplement in Longevity Science. #aging #agingscience #longevityscience #alphaketoglutarate #davidsinclairphd #agemanagement #healthwithoutrisk